Adam Bonislawski

1 day ago | genomeweb.com | Adam Bonislawski

NEW YORK – Seer reported first quarter revenues of $4.2 million after the close of market on Tuesday, up 35 percent from $3.1 million in the year-ago period. For the three months ended March 31, the Redwood City, California-based proteomics technology firm posted $2.9 million in product revenue, up 71 percent from $1.7 million a year ago. Service revenue totaled $1.2 million, up nearly threefold from $408,000 in Q1 2024, while other revenue was $60,000, up 67 percent from $36,000 a year ago.

2 days ago | 360dx.com | Adam Bonislawski

NEW YORK – Citing tariffs, cuts to academic funding, and lower biopharma spending, Quanterix on Monday lowered its full-year 2025 revenue guidance to between $120.0 million and $130.0 million.

2 days ago | genomeweb.com | Adam Bonislawski

NEW YORK – Citing tariffs, cuts to academic funding, and lower biopharma spending, Quanterix on Monday lowered its full-year 2025 revenue guidance to between $120.0 million and $130.0 million. The guidance, which excludes revenue from its Lucent Diagnostics business and the expected acquisition of Akoya Biosciences, would represent a year-over-year decline of 5 percent to 13 percent.

1 week ago | 360dx.com | Adam Bonislawski

NEW YORK – Reform of the Protecting Access to Medicare Act (PAMA) is once again a top priority for the clinical lab industry, but chaos in Washington D.C. could make legislative action a hard lift. And while in each of the last six years, Congress has passed one-year delays to PAMA reporting requirements and reimbursement cuts, such relief could be less likely this year, warned several industry stakeholders last week at the Executive War College (EWC) annual meeting in New Orleans.

1 week ago | 360dx.com | Adam Bonislawski

NEW YORK – For decades now consolidation has been one of the major trends in the clinical laboratory market as major players like Quest Diagnostics, Laboratory Corporation of America, and Sonic Healthcare have grown their businesses through the acquisition of smaller independent and hospital labs.